SynOx Therapeutics secures up to $35m debt financing with Hercules Capital to progress development and commercialisation of emactuzumab
Hercules Capital, Inc. (HTGC)
Last hercules capital, inc. earnings: 2/20 04:10 pm
Check Earnings Report
US:NYSE Investor Relations:
investor.htgc.com
Company Research
Source: PR Newswire
SynOx is developing emactuzumab - a potential best-in-class, next-generation CSF1(R) inhibiting monoclonal antibodyProvides flexible loan facility to support additional clinical work and activities to drive its successful registration and commercialisation Funding is additional to recent $75m Series B financingDUBLIN and OXFORD, England, April 30, 2024 /PRNewswire/ -- SynOx Therapeutics Limited ("SynOx" or the "Company"), the late-stage clinical biopharmaceutical company developing emactuzumab for the treatment of Tenosynovial Giant Cell Tumour (TGCT) and other diseases, today announces it has entered into a $35m loan facility with Hercules Capital, Inc. (NYSE: HTGC) ("Hercules").The transaction strengthens the Company's balance sheet as it executes TANGENT, a registrational Phase 3 study of emactuzumab, SynOx's potentially best-in-class CSF-1(R) inhibiting monoclonal antibody (mAb) for the treatment of TGCT. This loan facility provides SynOx with flexibility to fund additional clinic
Show less
Read more
Impact Snapshot
Event Time:
HTGC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HTGC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HTGC alerts
High impacting Hercules Capital, Inc. news events
Weekly update
A roundup of the hottest topics
HTGC
News
- Hercules Capital Announces Date of 2024 Annual Meeting of Stockholders [Yahoo! Finance]Yahoo! Finance
- Hercules Capital Announces Date of 2024 Annual Meeting of StockholdersBusiness Wire
- bluebird (BLUE) Tops on Q1 Sales, Zynteglo Progresses Well [Yahoo! Finance]Yahoo! Finance
- Hercules Capital: Solid 10% Yield, But Sky-High Valuation [Seeking Alpha]Seeking Alpha
- bluebird bio Reports First Quarter 2024 Results and Highlights Operational Progress and 2024 Guidance [Yahoo! Finance]Yahoo! Finance
HTGC
Earnings
- 5/2/24 - Beat
HTGC
Sec Filings
- 5/2/24 - Form 8-K
- 5/2/24 - Form 10-Q
- 4/23/24 - Form DEF
- HTGC's page on the SEC website